SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com/.
Geron Corporation (Nasdaq: GERN) $5.35. Today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company’s telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
An interim analysis of the Phase 1 trial was presented by Geron clinical scientists and collaborating principal investigators from Ingalls Memorial Hospital, Harvey, IL and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN.
What They Do: Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes.
Ariad Pharmaceuticals (Nasdaq: ARIA) $3.52. Today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL. The data are being presented this afternoon at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, IL.
Data on fifty-seven patients in seven dosing cohorts (2, 4, 8, 15, 30, 45 and 60 mg administered orally once daily) are being reported at ASCO. Fifty-three of the patients have resistant and refractory CML or Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Ninety-four percent of these 53 patients have been treated with, and were resistant to, at least two of the available first-line and second-line tyrosine kinase inhibitors for CML. Sixty-six percent of the patients were pretreated with three or more prior tyrosine kinase inhibitors, including imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna) and investigational agents.
What They Do: Ariad's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate.
Derma Sciences (Nasdaq: DSCI) $5.02. Today announced that its ALGICELL Ag wound dressings have received a CE mark for use in the European Union. SGS Group, the world's largest Control and Inspection Company, supervised the assessment and certification process.
The CE marking verifies that ALGICELL Ag has met all relevant European Union consumer safety, health or environmental requirements, and can be sold in the 30-nation European Economic Area (EEA).
What They Do: Derma Sciences is a global medical device and pharmaceutical company focused on wound care.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
